IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

$36.21

-1.16 (-3.10%)

(As of 09/6/2024 ET)

IDEAYA Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 13 Analyst Ratings

Based on 13 Wall Street analysts who have issued ratings for IDEAYA Biosciences in the last 12 months, the stock has a consensus rating of "Buy." Out of the 13 analysts, 12 have given a buy rating, and 1 has given a strong buy rating for IDYA.

Consensus Price Target

$55.70
53.82% Upside

High Forecast	$66.00
Average Forecast	$55.70
Low Forecast	$44.00

According to the 13 analysts' twelve-month price targets for IDEAYA Biosciences, the average price target is $55.70. The highest price target for IDYA is $66.00, while the lowest price target for IDYA is $44.00. The average price target represents a forecasted upside of 53.82% from the current price of $36.21.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	14 Buy rating(s)	13 Buy rating(s)	14 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$55.70	$52.08	$48.27	$31.46
Forecasted Upside	53.82% Upside	48.61% Upside	31.95% Upside	55.16% Upside

Get IDEAYA Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter.

Ad Deal Maker

The solution to fast food’s wage hike crisis

Shake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.

Learn more about this much-needed advancement and investment opportunity here.

IDYA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IDYA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IDEAYA Biosciences Stock vs. The Competition

Type	IDEAYA Biosciences	Medical Companies	S&P 500
Consensus Rating Score	3.08	2.77	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	53.82% Upside	1,206.55% Upside	11.36% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/27/2024	Citigroup 3 of 5 stars		Lower Target	Buy ➝ Buy	$60.00 ➝ $58.00	+46.80%
8/8/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$69.00 ➝ $66.00	+79.20%
8/7/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$61.00 ➝ $61.00	+66.85%
8/7/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$54.00 ➝ $54.00	+48.35%
8/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$60.00 ➝ $53.00	+47.22%
7/29/2024	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Zhu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
Get the Latest News and Ratings for IDYA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.
7/9/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$55.00 ➝ $62.00	+57.00%
7/8/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$63.00 ➝ $63.00	+55.94%
7/8/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Suvannavejh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00	+45.94%
5/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$53.00 ➝ $46.00	+11.81%
2/23/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/22/2024	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Chiang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
11/8/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$48.00 ➝ $44.00	+42.53%
8/8/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$33.00	+53.27%
8/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$33.00	+53.27%
3/23/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$26.00	+87.59%
11/18/2022	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$18.00 ➝ $24.00	+32.09%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:32 PM ET.

IDYA Forecast - Frequently Asked Questions

What is IDEAYA Biosciences' forecast for 2024?: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for IDEAYA Biosciences is $55.70, with a high forecast of $66.00 and a low forecast of $44.00.
Should I buy or sell IDEAYA Biosciences stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDYA shares.
Does IDEAYA Biosciences's stock price have much upside?: According to analysts, IDEAYA Biosciences's stock has a predicted upside of 49.95% based on their 12-month stock forecasts.
Has IDEAYA Biosciences been upgraded by Wall Street analysts recently?: Over the previous 90 days, IDEAYA Biosciences's stock had 1 upgrade by analysts.
What analysts cover IDEAYA Biosciences?: IDEAYA Biosciences has been rated by research analysts at BTIG Research, Citigroup, JPMorgan Chase & Co., Lifesci Capital, Mizuho, Oppenheimer, Royal Bank of Canada, Stifel Nicolaus, and Wedbush in the past 90 days.
Do Wall Street analysts like IDEAYA Biosciences more than its competitors?: Analysts like IDEAYA Biosciences more than other "medical" companies. The consensus rating for IDEAYA Biosciences is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IDYA compares to other companies.